Autonomix announces first patient enrolled, treated in follow-on phase to POC 2

Autonomix (AMIX) Medical, announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical trial, PoC 2, evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. “We’re executing on a bold vision to expand the reach of our technology beyond pancreatic cancer pain and into a broader range of high-need visceral cancer indications,” said Brad Hauser, CEO of Autonomix. “The start of patient treatment in our PoC 2 study represents a major milestone that reinforces our momentum and marks a critical step toward unlocking substantial clinical and commercial potential.”